| Carlos Hernandez-cassis, MD, MPH | |
|
10561 Jeffreys St Ste 211, Henderson, NV 89052-4268 | |
| (702) 636-3000 | |
| (702) 636-3000 |
| Full Name | Carlos Hernandez-cassis |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 50 Years |
| Location | 10561 Jeffreys St Ste 211, Henderson, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952366197 | NPI | - | NPPES |
| 258766100 | Medicaid | FL |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Claudia K Vogel Md Ltd | 1456376193 | 2 |
News Archive
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
The research was part of the Platelet-Oriented Inhibition in New TIA and minor ischemic stroke trial - a randomized, double-blind, placebo-controlled trial conducted between May 2010 and December 2017.
The best way to prevent the lethal spread of prostate cancer is by stopping cancer cell invasion of other tissues. Available treatments such as chemotherapy are toxic and can often be risky for older men, who are also most likely to get prostate cancer.
CELLINK AB (publ) has received an order for consumables for healthcare through an order from the National Board of Health and Welfare in Sweden, the order value is a total of 5,200,000 SEK.
› Verified 7 days ago
| Entity Name | Claudia K Vogel Md Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821131012 PECOS PAC ID: 1456376193 Enrollment ID: O20051011000980 |
News Archive
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
The research was part of the Platelet-Oriented Inhibition in New TIA and minor ischemic stroke trial - a randomized, double-blind, placebo-controlled trial conducted between May 2010 and December 2017.
The best way to prevent the lethal spread of prostate cancer is by stopping cancer cell invasion of other tissues. Available treatments such as chemotherapy are toxic and can often be risky for older men, who are also most likely to get prostate cancer.
CELLINK AB (publ) has received an order for consumables for healthcare through an order from the National Board of Health and Welfare in Sweden, the order value is a total of 5,200,000 SEK.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carlos Hernandez-cassis, MD, MPH 10561 Jeffreys St Ste 211, Henderson, NV 89052-4268 Ph: (702) 990-4530 | Carlos Hernandez-cassis, MD, MPH 10561 Jeffreys St Ste 211, Henderson, NV 89052-4268 Ph: (702) 636-3000 |
News Archive
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
The research was part of the Platelet-Oriented Inhibition in New TIA and minor ischemic stroke trial - a randomized, double-blind, placebo-controlled trial conducted between May 2010 and December 2017.
The best way to prevent the lethal spread of prostate cancer is by stopping cancer cell invasion of other tissues. Available treatments such as chemotherapy are toxic and can often be risky for older men, who are also most likely to get prostate cancer.
CELLINK AB (publ) has received an order for consumables for healthcare through an order from the National Board of Health and Welfare in Sweden, the order value is a total of 5,200,000 SEK.
› Verified 7 days ago
James B Gabroy, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1535 West Warm Spring Road, Suite 135, Henderson, NV 89014 Phone: 702-450-3385 Fax: 702-898-1699 | |
Dr. Poupak Ziaei, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2641 W Horizon Ridge Pkwy Ste 100, Henderson, NV 89052 Phone: 702-616-0091 Fax: 702-616-2329 | |
Dr. Jeannette Nee, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2865 Siena Heights Dr, Suite 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 | |
Wen Liang, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2621 W Horizon Ridge Pkwy, Suite 150, Henderson, NV 89052 Phone: 702-837-6368 Fax: 702-837-0685 | |
Randy James Ip, D.O. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2865 Siena Heights Dr Ste 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 | |
Linda Lou Johnson, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1501 W Sunset Rd, Henderson, NV 89014 Phone: 725-269-7001 Fax: 725-269-7003 | |
Dr. Daejoon Anh, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2865 Siena Heights Dr Ste 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 |